Clinical Trial Update: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly [Phase 2]

View source ↗

Summary

Phase 2 study assessing immunogenicity and safety of DTPa-HBV-IPV/Hib versus DTPa-IPV/Hib with concomitant hepatitis B administration, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib (Diphtheria and tetanus toxoids and acellular pertussis vaccine; Hepatitis B vaccine; Inactivated poliovirus vaccine; Haemophilus influenzae type b conjugate vaccine)
• DTPa-IPV/Hib (Diphtheria and tetanus toxoids and acellular pertussis vaccine; Inactivated poliovirus vaccine; Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Diphtheria | Phase 2 | Status: COMPLETED